6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2013.

Commission File Number ________________

Novogen Limited

(Translation of registrant’s name into English)

16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 Form 20-Fx Form 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes  o No x

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novogen Limited (Registrant)

(Signature) *

Andrew Bursill

Date 16 October 2013

* Print the name and title under the signature of the signing officer.

EX-99





Wednesday 16 October 2013



Novogen Comments on recent share price rise



Novogen today released the following statement by Dr Graham Kelly, CEO of Novogen Ltd. 



“The Company is unable to provide an explanation for the 45% rise in its ADR stock overnight on the NASDAQ exchange, other than the observation that is followed an article that appeared yesterday in the US press that speculated on the future of the Company. 



That article, in part, speculated on the possibility that the Company was engaged in discussions with another party in relation to its super-enzopyran drug technology. 



As was flagged in the 2013 Annual Report released recently, the Company is seeking to establish a structure that will facilitate its goalof delivering personalized chemotherapy on an individual patient basis. The Company currently is working towards establishing such a structure  thatwill  be announced when and if it is established. Until then, the Company is not in any position to provide any more details.” 



Yours sincerely, 







Lionel Mateo 

Company Secretary









Wednesday 16 October



Elvis Onyura

Senior Adviser, Listings Compliance (Sydney)

ASX Compliance Pty Ltd, 20 Bridge Street

Sydney NSW 2000

Dear Elvis,

Request for Trading Halt for Novogen Limited

In accordance with ASX Listing Rule 17.1, Novogen Limited (“the Company”) requests an

immediate trading halt in respect of its securities (ASX Code: NRT).

In requesting the trading halt, the Company provides the following information:

•     The trading halt is requested pending the release of a response to the speculations

published in the media in relation to a partnership with another entity;

•     Unless otherwise requested by the Company, the Company requests the trading halt

to remain in place until an announcement is made to the market;and

•     The Company is not aware of any reason why the trading halt should not be granted

or of any other information necessary to inform the market about the trading halt.

Yours sincerely,

Lionel Mateo

Company Secretary